Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?
CONCLUSIONS: Locally advanced ESCC patients with time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery > 8 weeks were associated with worse long-term survival.PMID:38536527 | DOI:10.1007/s00432-024-05696-4 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Jiacong Liu Linhai Zhu Xuhua Huang Zhongjie Lu Yanye Wang Yuhong Yang Jiayue Ye Chen Gu Wang Lv Chong Zhang Jian Hu Source Type: research

Risk of Esophageal Adenocarcinoma After Bariatric Surgery: A Meta-Analysis of Retrospective Studies
CONCLUSION: Our meta-analysis results suggest a reduced risk of esophageal cancer in patients with obesity after bariatric surgery.PROSPERO REGISTRATION: CRD 42024505177.PMID:38536625 | DOI:10.1007/s11695-024-07190-9 (Source: Cancer Control)
Source: Cancer Control - March 27, 2024 Category: Cancer & Oncology Authors: Chenglou Zhu Wenhan Liu Dongping Hu Lingzhi Peng Source Type: research

Surgery Adherence and Survival Outcomes in Patients With Locally Advanced (IIA-IVA) Cancer of the Lower Esophagus: A SEER Database-Based Study
DISCUSSION: Good surgical adherence can improve the prognosis of patients with locally advanced (IIA-IVA) lower esophageal cancer, while poor surgical adherence is associated with older age, unmarried, SEER classification of "distant," and squamous cell carcinoma.PMID:38532292 | DOI:10.1177/00031348241241727 (Source: The American Surgeon)
Source: The American Surgeon - March 27, 2024 Category: Surgery Authors: Jingsong Liu Hu Chen Chuannan Wu Source Type: research

Prognostic Risk Models Using Epithelial Cells Identify β-Sitosterol as a Potential Therapeutic Target Against Esophageal Squamous Cell Carcinoma
(Source: International Journal of General Medicine)
Source: International Journal of General Medicine - March 27, 2024 Category: General Medicine Tags: International Journal of General Medicine Source Type: research

Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real ‐world analysis
ConclusionNCIT is safe and provides potential survival benefits for patients with locally advanced ESCC. However, randomized phase 3 trial data is still needed. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Yao Zhang, Huiting Li, Bo Yu, Si Sun, Zhihuang Hu, Xianghua Wu, Yang Zhang, Bin Li, Yawei Zhang, Jiaqing Xiang, Jialei Wang, Hui Yu Tags: ORIGINAL ARTICLE Source Type: research

The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer
The human epidermal growth factor receptor (HER) family consists of four members, activated by two families of ligands. They are known for mediating cell–cell interactions in organogenesis, and their deregulation has been associated with various cancers, including breast and esophageal cancers. In particular, aberrant epidermal growth factor receptor (EGFR) and HER2 signaling drive disease progression and result in poorer patient outcomes. Nitric oxide (NO) has been proposed as an alternative activator of the HER family and may play a role in this aberrant activation due to its ability to induce s-nitrosation and phospho...
Source: Frontiers in Physiology - March 27, 2024 Category: Physiology Source Type: research

Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?
ConclusionsLocally advanced ESCC patients with time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery  >  8 weeks were associated with worse long-term survival. (Source: Journal of Cancer Research and Clinical Oncology)
Source: Journal of Cancer Research and Clinical Oncology - March 27, 2024 Category: Cancer & Oncology Source Type: research

Stigma, risks, and benefits of medicinal cannabis use among Australians with cancer
ConclusionFindings highlight the need for robust data regarding the harms and efficacy of medicinal cannabis and dissemination of such information among healthcare professionals and to patients who choose to use the substance. Ensuring healthcare professionals are equipped to provide non-judgmental and evidence-based guidance may mitigate potential safety and legal risks. (Source: Supportive Care in Cancer)
Source: Supportive Care in Cancer - March 27, 2024 Category: Cancer & Oncology Source Type: research

Risk of Esophageal Adenocarcinoma After Bariatric Surgery: A Meta-Analysis of Retrospective Studies
ConclusionOur meta-analysis results suggest a reduced risk of esophageal cancer in patients with obesity after bariatric surgery.PROSPERO RegistrationCRD 42024505177.Graphical Abstract (Source: Obesity Surgery)
Source: Obesity Surgery - March 27, 2024 Category: Surgery Source Type: research

Is neoadjuvant chemotherapy combined with immunotherapy really better than neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma?
This study comparing neoadjuvant chemotherapy combined with immunotherapy (NACI) versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma provides substantial insights into the evolving landscape of cancer treatment modalities. (Source: The Journal of Thoracic and Cardiovascular Surgery)
Source: The Journal of Thoracic and Cardiovascular Surgery - March 27, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Kexun Li, Jiapeng Yang, Ynchao Huang Tags: Letter to the Editor Source Type: research

Influence of Neoadjuvant Immunotherapy-Chemotherapy on Perioperative Outcomes in Locally Advanced Esophageal Adenocarcinoma
CONCLUSION: The addition of immunotherapy to neoadjuvant chemotherapy for locally advanced esophageal adenocarcinoma does not appear to alter perioperative short-term outcomes significantly after esophagectomy.PMID:38530527 | DOI:10.1245/s10434-024-15186-z (Source: Ann Oncol)
Source: Ann Oncol - March 26, 2024 Category: Cancer & Oncology Authors: Yehonatan Nevo James Tankel Hedi Zhao Jaime Ramirez Jonathan Cools-Lartigue Carmen Muller Thierry Alcindor Lorenzo Ferri Source Type: research

ASO Visual Abstract: Development and Validation of PET/CT-Based Nomogram for Preoperative Prediction of Lymph Node Status in Esophageal Squamous Cell Carcinoma
Ann Surg Oncol. 2024 Mar 26. doi: 10.1245/s10434-023-13841-5. Online ahead of print.NO ABSTRACTPMID:38530531 | DOI:10.1245/s10434-023-13841-5 (Source: Ann Oncol)
Source: Ann Oncol - March 26, 2024 Category: Cancer & Oncology Authors: Shaoyuan Zhang Linyi Sun Danjie Cai Guobing Liu Dongxian Jiang Jun Yin Yong Fang Hao Wang Yaxing Shen Yingyong Hou Hongcheng Shi Lijie Tan Source Type: research

HIV infection and esophageal cancer in Sub-Saharan Africa: a comprehensive meta-analysis
This study conducted an exhaustive computerized search of databases, including Medline/PubMed, Embase, Web of Science, Scopus, Cochrane library, and African Journals Online, to identify eligible studies up to October 2023. HIV infection was the exposure, esophageal cancer risk was the outcome, and healthy subjects with no cancer history served as comparators. Study quality was assessed using the Newcastle-Ottawa scale, and potential publication bias was evaluated through funnel plots and the Egger test. Meta-analyses were conducted using Stata 17.0 software and involved a thorough examination of 98,397 studies. Out of thes...
Source: AIDS Reviews - March 26, 2024 Category: Infectious Diseases Authors: Gabriel Kamsu-Tchuente Eugene J Ndebia Source Type: research

Cancers, Vol. 16, Pages 1291: Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT
Conclusion(s): Real-world data showed no significant OS improvement for FLOT-treated patients compared to anthracyclin triplets, despite more staging laparoscopies. However, FLOT patients demonstrated higher rates of neoadjuvant therapy completion, proceeding to adjuvant therapy, and increased pCR rates. Therefore, we recommend the continued use of neoadjuvant FLOT therapy in the current clinical setting. (Source: Cancers)
Source: Cancers - March 26, 2024 Category: Cancer & Oncology Authors: Julie F. M. Geerts Charl ène J. van der Zijden Pieter C. van der Sluis Manon C. W. Spaander Grard A. P. Nieuwenhuijzen Camiel Rosman Hanneke W. M. van Laarhoven Rob H. A. Verhoeven Bas P. L. Wijnhoven Sjoerd M. Lagarde Bianca Mostert Tags: Article Source Type: research

Laparoscopic or open abdominal surgery with thoracotomy for patients with oesophageal cancer: ROMIO randomized clinical trial
CONCLUSIONS: Patient-reported physical function in the 3 months post-randomization provided no evidence of a difference in recovery time between hybrid and open surgery, or a difference in cost-effectiveness. Both approaches to surgery were completed safely, with a similar risk of key complications, suggesting that surgeons who have a preference for one of the two approaches need not change their practice.PMID:38525931 | PMC:PMC10961947 | DOI:10.1093/bjs/znae023 (Source: The British Journal of Surgery)
Source: The British Journal of Surgery - March 25, 2024 Category: Surgery Authors: ROMIO Study Group Source Type: research